Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.55 | — | 19.87 | 5.09 | 3.10 | 2.31 | 0.76 | 7.46 | 14.81 | — | — | — | 12.84 | 6.17 | 6.27 | 3.87 | 3.73 | 2.63 | 2.59 | 3.20 | 5.53 |
| — | — | +2503.7% | -31.7% | -79.1% | — | — | — | +15.3% | — | — | — | +244.1% | +134.6% | +142.1% | +21.0% | -32.4% | -79.7% | -94.1% | -53.8% | +52.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -220.6% | — | -176.3% | -65.5% | -46.1% | -29.4% | -33.2% | -71.6% | -475.8% | — | — | — | -107.4% | -46.7% | -40.2% | -26.5% | -19.7% | -15.4% | -12.1% | -13.0% | -6.0% |
| — | — | -431.0% | +8.5% | +90.3% | — | — | — | -342.9% | — | — | — | -444.3% | -203.7% | -232.2% | -104.0% | -229.6% | -61.2% | +77.5% | +36.5% | +44.6% | |
| ROA | -164.8% | -77.4% | -94.3% | -51.4% | -37.6% | -25.8% | -27.2% | -41.5% | -130.2% | -78.1% | -11.8% | -217.4% | -89.1% | -39.4% | -31.6% | -22.6% | -18.6% | -14.9% | -11.7% | -12.6% | -5.9% |
| — | -200.0% | -246.4% | -23.9% | +71.1% | +66.9% | -130.0% | +80.9% | -46.2% | -98.0% | +62.6% | -864.1% | -377.9% | -165.2% | -169.8% | -78.6% | -217.9% | -63.4% | +74.2% | +35.1% | +42.9% | |
| ROIC | — | — | — | — | — | -311.7% | -1643.4% | — | — | — | — | — | -419.0% | -174.4% | -450.0% | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.80 | 2.95 | 1.27 | 5.80 | 4.60 | 7.65 | 10.68 | 3.59 | 2.66 | 1.24 | 1.60 | 2.39 | 2.87 | 11.00 | 4.72 | 4.68 | 12.86 | 28.11 | 34.46 | 30.54 | 42.52 |
| — | -61.5% | -88.1% | +61.6% | +72.8% | +514.9% | +565.4% | +50.4% | -7.1% | -88.7% | -66.0% | -49.0% | -77.7% | -60.9% | -86.3% | -84.7% | -69.8% | -49.8% | +822.4% | +117.5% | +27.1% | |
| Quick Ratio | 5.80 | 2.95 | 1.27 | 5.80 | 4.60 | 7.65 | 10.68 | 3.59 | 2.66 | 1.24 | 1.60 | 2.39 | 2.87 | 11.00 | 4.72 | 4.68 | 12.86 | 28.11 | 34.46 | 30.54 | 42.52 |
| — | -61.5% | -88.1% | +61.6% | +72.8% | +514.9% | +565.4% | +50.4% | -7.1% | -88.7% | -66.0% | -49.0% | -77.7% | -60.9% | -86.3% | -84.7% | -69.8% | -49.8% | +822.4% | +117.5% | +27.1% | |
| Interest Coverage | — | -9.05 | — | — | — | — | — | — | -23.12 | -2.73 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANVS stock.
Annovis Bio, Inc.'s current P/E is -0.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Annovis Bio, Inc.'s business trajectory between earnings reports.